Special Edition: Share the Science with Crystal Weaver – Benefits of Music Therapy for Cancer Patients Receiving Cord Blood or Bone Marrow Transplants

Special Edition: Share the Science with Crystal Weaver – Benefits of Music Therapy for Cancer Patients Receiving Cord Blood or Bone Marrow Transplants

As the holidays approach, we are reminded of the need for compassion in today’s world. For anyone undergoing cancer treatment, whether it is chemotherapy, a bone marrow transplant, a cord blood transplant or other innovative treatment, the healing process can be an emotional and physical roller-coaster. Music can help during these difficult times.

Save the Cord Foundation and Mediware, Inc. are proud to announce a special holiday edition in our Share the Science series — a discussion with Crystal Weaver, MA, PLPC, CRC, MT-BC, who will discuss the history of music therapy, therapeutic benefits and common misconceptions, as well as highlights ways cancer patients can benefit from this complimentary therapy during their treatment process.

Join us Thursday, December 14th, 2017 to learn about the concept of music therapy in the medical model and insightful information regarding the benefits of music therapy for individuals diagnosed with cancer throughout the treatment process. Real-world examples will be provided by Crystal Weaver, a board-certified music therapist with more than 14 years of experience providing individual music therapy services to individuals diagnosed with leukemia, lymphoma, and multiple myeloma. Examples will allow attendees to understand how music therapy services can increase patient satisfaction while also addressing emotional, social, spiritual, and physical issues associated with treatment.

Highlights of this presentation will include:

  • How to define music therapy in the medical model
  • About common music therapy goals and interventions utilized for individuals diagnosed with fluid cancers
  • About common misconceptions of music therapy in the medical model
  • How to effectively partner with board-certified music therapists to address medical issues
  • The educational and certification requirements to practice music therapy in the medical model

 

Please join us for this exciting free webinar. . .

Share the Science
featuring
Crystal Weaver
“Establishing Music Therapy as a Medical Model that Benefits Cancer Patients”

Thursday, December 14th | 1 p.m. – 2 p.m. Central Time

Free online webinar – Open to the Public
 REGISTER ONLINE HERE

 

 

REGISTER HERE for SHARE THE SCIENCE (Live Webinar – Free, Open to all): Crystal Weaver discussing “Establishing Music Therapy as a Medical Model that Benefits Cancer Patients”

 

   *  *  *

 

Save the Cord Foundation wishes to thank Crystal Weaver 
for sharing her valuable insight and expertise
with our Share the Science community.
We also wish to thank Mediware, Inc.
for their continued generous support of this program. 

 

 

 

Share the Science continues to be a popular series within the cord blood community and beyond. We welcome your input on the series and suggestions for future speakers. Give your feedback here.

powerhouses of science - cord blood research
Previous Share the Science presentations have been archived for your reference. Discover the work of leading scientists and cord blood industry experts through this educational series. View the archive now.

Share the Science is made possible thanks to the generous support of Mediware, Inc.

 

Share the Science: Using Amniotic Membrane in Ocular Surface Disease with Dr. Roxana URSEA

Share the Science: Using Amniotic Membrane in Ocular Surface Disease with Dr. Roxana URSEA

As our readers know well, our primary focus here at Save the Cord Foundation is to encourage the preservation of cord blood stem cells which can be used to treat 80+ diseases. Yet, we also recognize the growing importance of perinatal stem cells, cord tissues, uses for the placenta, amniotic membrane, etc. Scientists agree we are just on the tip of the iceberg in understanding how to use these “by-products” of the birthing process more wisely. We should not simply throw them away without asking first. . . do they have a potential second use? 

With this thought in mind, Save the Cord Foundation and Mediware, Inc. are proud to announce the next edition in our Share the Science series — a real world example of how the amniotic membrane (a by-product of the birthing process) is currently used in ophthalmology and as well as potential uses for this medical resource in the near future. 

UPDATE: RECORDING NOW AVAILABLE, CLICK LINK BELOW — On October 24th, 2017, Save the Cord Foundation and Mediware, Inc. will welcome Dr. Roxana URSEA from the University of Arizona Department of Ophthalmology and Visual Sciences. Dr. Ursea will discuss how the amniotic membrane is currently used and how it can help heal ocular surface disease (OSD).  She will discuss its clinical significance, her own research in this area and data from various clinical applications.

amniotic membrane from placenta for ocular surface disease

Amniotic membrane for the eye – Share the Science with Dr. Roxana Ursea

According to the Bascom Palmer Eye Institute at the University of Miami, ocular surface diseases affect the “surface of the cornea—the transparent layer that forms the front of the eye. These diseases include dry eye syndrome, meibomian gland dysfunctionblepharitis, rosaceous, allergies, scarring from glaucoma medications, chemical burns, thermal burns, and immunological conditions such as Mucous Membrane Pemphigoid and Sjogren’s Syndrome.
Ocular surface diseases can severely affect eyesight and quality of life. Symptoms may include blurry vision, discomfort or pain, redness and itching, and in severe cases, blindness due to corneal scarring.” (source: Bascom Palmer Eye Institute – OSD overview ).

Use of amniotic membrane for the eye has been common practice for several years and indications for its use have continued to expand. The reasons for its use are numerous. Notably, amniotic membrane, the innermost layer of the placenta, can stabilize the ocular surface. It exhibits strong anti-inflammatory properties, promotes healing without scarring, and supports stem cell expansion. In patients with moderate to severe dry eye, cryo-preserved amniotic membrane plays a role in corneal nerve regeneration and restores corneal nerve integrity.

During this webinar, Dr. Ursea will discuss the important role the amniotic membrane plays in healing a variety of ocular surface diseases. She will share data for how to best utilize these clinical applications. She will discuss in detail how the amniotic membrane can be used as a biological bandage for superficial epithelial defects or as a permanent graft for deeper defects, including stromal defects, post-infectious ulcers, recurrent erosions/endothelial basement membrane dystrophy, small corneal perforations, inflammatory conditions, and chemical burns. She will also cover how it is especially beneficial in ocular surface reconstruction cases as well as in selected post-surgical procedures.

Please join us for this exciting free webinar. . .

Share the Science
featuring
Dr. Roxana Ursea
“Clinical Applications of Amniotic Membrane in Ocular Surface Disease”
Tuesday, October 24th | 2 p.m. – 3 p.m. Central Time

Free online webinar – Open to the Public
RECORDING NOW AVAILABLE – REGISTER ONLINE HERE

Attendees will learn about the:

  • Role of amniotic membrane in promoting regenerative healing
  • Clinical significance of amniotic membrane and the rationale for its use
  • Science behind amniotic membrane use and its ocular indications and outcomes, including data from clinical cases
  • Pearls and pitfalls in using the amniotic membrane products in your practice
REGISTER HERE for SHARE THE SCIENCE (Recording of Live Webinar Now Available – Free, Open to all): Dr. Roxana URSEA discusses “Clinical Applications of Amniotic Membrane in Ocular Surface Disease”

About Dr. Roxana Ursea:

Dr. Ursea is a clinical associate professor of ophthalmology at the University of Arizona Department of Ophthalmology and Visual Sciences.  After completing her residency in ophthalmology at New York-Presbyterian Hospital/Weill Cornell and University of Maryland in Baltimore, Dr. Ursea expanded her clinical expertise with specialized training in uveitis and ocular immunology at the National Eye Institute of NIH in Bethesda, Maryland. She completed a second fellowship in cornea, external diseases, and refractive surgery at the University of California in San Diego.

Dr. Ursea is active in many professional organizations and has published in major peer-reviewed journals. She is a recognized national and international expert in ocular imaging, in particular, high-frequency ultrasound, and has received numerous awards, including the American Academy of Ophthalmology’s Achievement Award and the University of Arizona’s prestigious Vernon and Virginia Furrow Award for Excellence in Teaching Clinical Sciences.

Her clinical interests include keratoconus, laser vision correction, and challenging uveitis cases while her research interests include exploring new applications of high frequency ultrasound and new therapeutic modalities for anterior segment disorders. She has an active clinical and surgical practice at Northwest Medical Center in Tucson, Arizona.

Save the Cord Foundation wishes to thank Dr. Ursea
for sharing her valuable insight and expertise
with our Share the Science community.
We also wish to thank Mediware, Inc.
for their continued generous support of this program. 

 

Share the Science continues to be a popular series within the cord blood community and beyond. We welcome your input on the series and suggestions for future speakers. Give your feedback here.

powerhouses of science - cord blood research
Previous Share the Science presentations have been archived for your reference. Discover the work of leading scientists and cord blood industry experts through this educational series. View the archive now.

Share the Science is made possible thanks to the generous support of Mediware, Inc.

 

Share the Science: Dr. Kevin Burns, Treating Acute Kidney Injury

Share the Science: Dr. Kevin Burns, Treating Acute Kidney Injury

 

RECORDING COMING SOON:  Acute kidney injury (AKI) is incredibly common, affecting as many as 20% of hospitalized patients according to the National Kidney Foundation.  Sadly, despite years of research, doctors have not found an effective treatment for acute kidney injury. As a result, mortality rates remain high at 1-5% of hospitalized patients. However, the research of Dr. Kevin D. Burns from the Ottawa Hospital Research Institute is providing new hope for patients and cord blood may be the key.

Save the Cord Foundation and Mediware, Inc. are proud to welcome Dr. Kevin Burns to speak about his research on the next edition of our popular webinar series, Share the Science (learn more about the series here). A professor of medicine in the division of Nephrology at the Department of Medicine of the Ottawa Hospital and University of Ottawa, Dr. Burns has dedicated his career to kidney research.

Using cord blood for acute kidney injury

Image courtesy of yodiyim at FreeDigitalPhotos.net

Dr. Burns will present research findings from his laboratory on the reparation properties of extracellular vesicles (exosomes) isolated from human cord blood-derived endothelial colony forming cells (ECFCs) in experimental Acute Kidney Injury. When infused into mice with ischemia/reperfusion Acute Kidney Injury, ECFC exosomes protect against loss of kidney function, prevent inflammatory cell infiltration into the kidneys, and inhibit apoptotic responses. Using next-generation sequencing of small RNAs, his lab found that ECFC exosomes are highly enriched in microRNA-486-5p, which targets the pro-apoptotic factor PTEN. Data from his lab supports the notion that infused exosomes transfer microRNA-486-5p to injured kidney endothelial cells after ischemia/reperfusion Acute Kidney Injury, leading to inhibition of PTEN and subsequent activation of the pro-survival Akt pathway. Finally, he will present data indicating that infused ECFC exosomes selectively home to the injured kidneys after Acute Kidney Injury. This webinar will present information suggesting that ECFC-derived exosomes hold promise as potential therapeutic agents in humans with Acute Kidney Injury.

Join us for this presentation. . .

Share the Science with Dr. Kevin D. Burns
“Cord Blood Endothelial Colony Forming Cell-Derived Exosomes in Acute Kidney Injury”
Wednesday, September 20, 2017 at 3-4pm Central Time
Free to register. Open to the public.

REGISTER HERE for SHARE THE SCIENCE: Dr. Kevin Burns, “Cord Blood Endothelial Colony Forming Cell-Derived Exosomes in Acute Kidney Injury”

 

Recommended reading: https://www.ncbi.nlm.nih.gov/pubmed/26073035

During the webinar, attendees will learn about:

  • Clinical significance of acute kidney injury and the rationale for the use of cellular therapy
  • Effects of administration of ECFCs in experimental ischemia/reperfusion Acute Kidney Injury
  • Potential role of ECFC-derived exosomes in mediating therapeutic responses in Acute Kidney Injury in vivo and in cell culture models
  • Potential role of microRNA transfer in the kidney in mediating the protective effects of exosome treatment

About Kevin D. Burns MD, CM, FRCP(C):

Dr. Burns is a professor of medicine in the division of Nephrology at the Department of Medicine of the Ottawa Hospital and University of Ottawa. He is senior scientist and director of the Kidney Research Centre of the Ottawa Hospital Research Institute and is cross-appointed to the Department of Cellular and Molecular Medicine. Dr. Burns’ research has focused on the function and regulation of the intrarenal renin-angiotensin system in diabetic nephropathy and hypertension and the pathogenesis and treatment of acute kidney injury.

He received his BSc and MD degrees from McGill University and completed internal medicine residency and clinical nephrology fellowship training at the University of Ottawa. Dr. Burns also undertook basic science research training at Vanderbilt University Medical Center. His laboratory has been supported by funds from the Canadian Institutes of Health Research, the Kidney Foundation of Canada, and the Canada Foundation for Innovation/Ontario Innovation Trust.

Dr. Burns is past president of the Canadian Society of Nephrology and is chair of the steering committee for the KRESCENT Program, a national kidney research training program launched by the Canadian Society of Nephrology, the Kidney Foundation of Canada, and the Canada foundation for Innovation/Ontario Innovation Trust. In 2010, Dr. Burns received the Medal for Research Excellence from the Kidney Foundation of Canada in recognition of his contributions to kidney research in Canada. To learn more about the KRESCENT program, please click here. 

______________________

We wish to thank Dr. Kevin Burns for sharing his
valuable insight on cord blood and kidney research
with our Share the Science community.
We also wish to thank Mediware, Inc.
for their generous support making this webinar possible. 

Share the Science continues to be a popular series within the cord blood community and beyond. We welcome your input on the series and suggestions for future speakers. Give your feedback here.

powerhouses of science - cord blood research
Previous Share the Science presentations have been archived for your reference. Discover the work of leading scientists and cord blood industry experts through this educational series. View the archive now.

Share the Science is made possible thanks to the generous support of Mediware, Inc.

 

Cord Blood Used to Treat Child with Hurler Syndrome, Genetic Disorder

Cord Blood Used to Treat Child with Hurler Syndrome, Genetic Disorder

Meet Lyla Edgington. Lyla was first diagnosed with Hurler Syndrome (MPS Type I) on April 4th, 2016 when she was just 7 months old.  Her doctors said she needed a stem cell transplant and that cord blood would give her the best chances at overcoming this life-threatening genetic disorder.

Lyla’s doctors and parents began to worry when their pediatrician, Dr. Katherine Lichtsinn at Scottsdale Children’s Group noticed a heart murmur during her 4 month check-up. Returning for another check-up at 6 months, Helen, Lyla’s mother, pointed out a sharp curve in Lyla’s spine that she had noticed. It was then that her doctor suspected a possible genetic disorder and referred them to a specialist at Phoenix Children’s Hospital.

In Phoenix, Lyla underwent numerous blood tests hoping to rule out MPS. Unfortunately, this would not be the case. Not only were their fears confirmed but the medical team concluded that Lyla had the most severe form of the disease, MPS Type 1, better known as Hurler Syndrome or Hurler’s disease.

Our world came crashing down that day, but luckily the weeks to follow were full of good news. To say life was like a storm on April 4th, 2016 on the day we received Lyla’s diagnosis, is an understatement…..the tears flowed like a monsoon, my body shook like an earthquake, and the life I envisioned for my daughter was torn to the ground. I truly thought our world had ended.Helen Edgington, Lyla's Mother

Helen was devastated, and worse, she felt responsible even though there was nothing she could have done differently.  She and her husband, Steve, had given birth to a beautiful little girl. She was perfect in every way. Hundreds of questions came pouring through the emotions as they wondered “Why us?”

MPS I (Hurler, Hurler-Scheie, Scheie syndrome)
MPS I, along with six other MPS diseases is a mucopolysaccharide disease that is relentlessly progressive and potentially fatal. MPS I has also been called Hurler, Hurler-Scheie and Scheie syndrome . Hurler takes its name from Gertrude Hurler, the doctor who described a boy and girl with the condition in 1919. In 1962, Dr. Scheie, a consultant ophthalmologist, wrote about some of his patients who were more mildly affected. Individuals who seem not to fit clearly in either the severe or the mild end of the disease were said to have Hurler/Scheie. The specific disease names have been replaced with the designations attenuated (diminished severity) and severe MPS I. There is no cure for MPS diseases, but there are ways of managing and treating the problems they cause.

(Source: National MPS Society, http://mpssociety.org/mps/mps-i/ )

Child with Hurlers Syndrome treated with Cord Blood

Lyla, diagnosed at 7 months with MPS Type 1 (Hurler Syndrome)

Helen still remembers those initial hours, “As a parent your duty is to protect your child and I had failed within the first moments she was created. I passed on a defective gene that would cripple her body, deteriorate her brain, and end her precious life after it had barely begun. I held my beautiful 7 month old daughter so tight. I sobbed because I couldn’t bear to watch her smile fade away and her energy disappear day by day over the next couple years. It wasn’t possible. Lyla was too perfect, she had too much personality, she was too smart, and she could already throw a tennis ball so well. But at that moment… Lyla was still Lyla and I couldn’t help but smile when she did and enjoy every moment with her. Everything had changed but nothing had changed.”

Right away, Dr. Kristin Lindstrom at the Phoenix Children’s Hospital recommended a stem cell transplant. Initially, they thought this meant a bone marrow transplant and Dr. Lindstrom referred them to Dr. Paul Orchard at the University of Minnesota. Dr. Orchard explained that transplants for MPS patients have greatly improved over the last several years. He explained that cord blood could be the best choice for Lyla and give her the best chances for a successful transplant.

The goal was not simple. In order to be successful, the transplant needed to rid Lyla’s body of her own cells (because they were genetically faulty) and replace her cells with healthy new ones. Although the actual transplant lasts only a few minutes, the whole healing process would be quite long and span several months.

Helen and Steve were encouraged by this possible treatment and agreed that this was their best option for young Lyla. The wheels were put in motion. They would go to Minnesota for treatment. Lyla’s parents received approval from insurance and doctors began to search for a donor. It was a race against the clock as the disease was constantly working against them, deteriorating brain cells. Luckily, a match was found and it was a perfect 6 out of 6 match! The transplant date was set for July 25th, 2016.

The procedure lasted 25 minutes and was much like a typical blood transfusion. In accordance with donor rules, Lyla’s parents were not told where the donor was born or the identity of the generous family. They only know that the donated cord blood came from a little girl born in May 2013. She could be from anywhere in the world.

Looking back the reality of the situation, it should have been much scarier than it was. But, we were just so happy and thankful Lyla had the option of a stem cell transplant and that she had a perfect 6 out of 6 cord blood match. We knew there was a long road ahead, but we were very optimistic!Helen Edgington, Lyla's Mother
Hurlers Syndrome Treated with Cord Blood

A cord blood donation gave a new life to Lyla.

Hurler Syndrome is a progressive genetic disease. If you don’t treat it, it will gradually cause severe physical and mental damage. Lyla’s parents knew this and this is why timing was so crucial in her case. Luckily, Lyla was diagnosed early and did not have too much damage prior to the transplant. This meant her chances were good. However, because of the nature of the disorder, Lyla’s parents and doctors were not expecting to see major improvements necessarily in her mental and physical functions but what they hoped was that the progression of the disorder would stop. The goal was to stop the disorder from becoming worse. Questions remained as to if some damage would continue to occur following transplant or would the transplant be effective immediately?

The first few weeks after the transplant were really difficult because of the impact of the chemotherapy. Lyla suffered from low energy and clearly her spirits were down. However, after the first month, doctors confirmed that the transplant had fully engrafted (the donor cells had been accepted by her body). Success!  From there it is was smooth sailing. . . she returned to being a happy girl most of the time while living under constant medical supervision (remember, she was not even a year old at the time).

When discussing stem cell transplants, doctors often refer to the “first 100 days.” Although not always applicable to every case, this milestone often indicates whether a transplant has been “successful” or not. In Lyla’s case, she was doing great and around day +95 her parents started preparing for their flight home. Then, the phone rang. Lyla’s blood tests came back with issues.

Lyla’s parents explained, “The transplant worked but for some unknown reason the new white cells were creating antibodies against the new platelets and red blood cells. Lyla’s immune system needed to be wiped out again to kill the antibodies and we had to hope the new ones wouldn’t do the same thing. This was a huge bump in the road for us and really tore down our spirits. It took another very long 5 months of Lyla on high dose steriods, tons of infusions, very little sleep, and at a huge risk for infection but luckily it worked and the bad antibodies didn’t return! Overall, it took a full 9 months after transplant to know that it was an overwhelming success.”

Post transplant Lyla is developing normally.

Post-transplant, Lyla has been blossoming!

Success. What a magic word! Success. This word meant hope to the Edgingtons. Success, meant their daughter might beat the odds. Success meant life and quality of life!

Today, the Edgingtons are just starting to turn the corner on this battle but they have been very encouraged by the results. The transplant worked and despite some complications around day 95, it appears that the transplant stopped damage caused by the disorder almost immediately. Based on various tests, Lyla did not experience any further damage post-transplant.

“She is developmentally on track,
so we feel confident the transplant
stopped damage to her brain,”
says Lyla’s mother.

Her parents realize how lucky they are. The stars aligned for Lyla. She had excellent doctors. She had a 6 out 6 stem cell match, thanks to cord blood. She had pro-active parents and grandparents who did everything they could to help her. In the end, it literally took everyone but they have been fortunate in many ways.

Looking to the future, we asked Helen what advice she has for parents, health professionals and even students interested in pursuing STEM careers with an interest in cord blood.

For Parents:

My advice for parents is to never ignore anything that seems odd about your baby. It took me a month or so to mention the curve in Lyla’s spine because I thought it could have been a normal baby thing or something she would grow out of. 

For Health Professionals:

My advice for health professionals, is to continue to do the amazing work you’re doing and saving so many lives! I have so much appreciation for the medical field and doctors who devote their life to finding cures to all the horrible diseases out there. It’s truly incredible!!

For STEM Students:

For students, I encourage you to use your social media skills and networks to help raise awareness for cord blood donation and it’s amazing benefits!

In honor of Lyla’s donor and to help build awareness for MPS / Hurler Syndrome as well as the need for cord blood donors, Helen and Steve have created a beautiful video detailing Lyla’s story. Watch it here:

Make a difference in your community.
Join us for World Cord Blood Day on November 15th, 2017!
Learn more, click here.

 

 

Interview with Diane Paradise: How Cord Blood Stopped Her Hodgkins Lymphoma

Interview with Diane Paradise: How Cord Blood Stopped Her Hodgkins Lymphoma

Save the Cord Foundation recently sat down to speak with Diane Paradise who beat cancer thanks to a cord blood transplant. In this interview, Diane tells us about her long battle with Hodgkins Lymphoma and how close she came to dying. To see her now, you would never know that she had ever been sick.

Diane has a wonderfully infectious personality. When you meet her, you immediately smile. She is positive in every way but it is not until you hear Diane tell her story that you realize how special (and lucky) she is.

WATCH THE VIDEO HERE.

 

She was 24 when initially diagnosed with Nodular lymphocyte predominant Hodgkin disease. Her life changed in an instant. A small lump under her arm turned into non-stop chemo and hospital visits, cycles of improvement only to be diagnosed again with cancer, treatments which became less and less effective. . .

Throughout the years, Diane explored new treatments, new doctors and challenged the predictions regarding her chances to conquer this horrible disease. She never gave up. She new her best chance was herself.

It was her determination that led her to the specialists at Johns Hopkins. She was invited to participate in a clinical trial and then randomly selected to receive a cord blood transplant. After much research of her own, Diane decided to go forward with her participation in the study. It was a decision that would ultimately save her life.

She received a double cord blood stem cell transplant on December 3rd, 2013. The cords come from donors who she will never meet. She knows one of the cords came from a little girl born on July 21, 2011. Just think. . . she is about to turn 6 and has already saved someone’s life!

In this short interview with Diane, we talk to her about life before and after her cord blood transplant. She reminds of how she is still trying to get used to being “cancer-free” because for years cancer was all she knew. She became one with it. Today, she is proud to say that she has been officially “released from Oncology” and no longer lives in fear.

Read more about Diane here. 

Diane has one message to those who are expecting a baby. . . “Save the Cord!”

 

We wish to thank Diane Paradise

for taking the time to share her story with us at

Save the Cord Foundation. 

 

#WeCanICan: #BeatCancer with Cord Blood

#WeCanICan: #BeatCancer with Cord Blood

Learn more about our on-going series “# WeCanICan : Beat Cancer with Cord Blood” and register to be a part of our Parents community. We are committed to cord blood education for parents and the medical community worldwide. Show your support by sharing this information with others, especially expectant parents.

Update on Autism Clinical Trials: Interview with Dr. Michael Chez

Update on Autism Clinical Trials: Interview with Dr. Michael Chez

Save the Cord Foundation recently interviewed Dr. Michael Chez (Sutter Health / Sutter Neurological Institute) about the encouraging results coming out of his autism clinical trials using cord blood. In addition, Dr. Chez spoke about the exciting work in this area also being done at Duke University by Dr. Joanne Kurtzberg and Geraldine Dawson, PhD.

Autism is a complicated developmental disability that affects as many as 1 in 68 children in the United States alone, according to the Centers for Disease Control and Prevention (source: CDC.gov). Imagine how many lives could be changed, if we could find a cure or treatment for autism. Many researchers feel that using a child’s own autologous cord blood could be the key to unlocking this mystery via the emerging field of regenerative medicine.

In this interview, Dr. Chez details the background and results of his clinical trials studying cord blood’s effect on autism. This particular study is significant because it included a placebo which is not always the case in cord blood research. Specifically, this was a double-blind placebo crossover study meaning that ultimately all participants received their cord blood.

Tip for Parents
It is interesting to note that in this particular study and many like it, participants received their own cord blood via private banking. Several private cord blood banks around the world lead (or participate in) on-going research using cord blood. In some cases, parents who store their cord blood privately may be asked by their bank if they would like to participate in a clinical trial (covering a variety of topics). For some parents having this option is important because they anticipate health issues for their baby based on family history or an issue identified during pregnancy. However, not all cord blood banks participate in this type of research. If this is important to you, do your research on the bank you are considering and make sure that they follow the highest standards in terms of storage criteria and processing.

Watch the video now and learn about the latest research using cord blood to potentially treat autism:

Autism and Cord Blood Clinical Trials

Save the Cord Foundation wishes to thank Dr. Michael Chez
for sharing his valuable insight on autism clinical trials using cord blood. 

 

Test your knowledge on cord blood!

 

A Father’s Story: Cord Blood Saved His Son’s Life

A Father’s Story: Cord Blood Saved His Son’s Life

Erik Praskins spoke about his son’s battle with leukemia at the Arizona Cord Blood Conference 2017 held in Phoenix, Arizona. His story is not unique yet, it is hard for many of us to imagine. Watch Erik tell his story below. . .

Children are sometimes described as “angels among us.” Indeed, every parent has felt that emotional moment of amazement looking into their child’s eyes or watching them discover something new in the world. Everytime they walk in the room, our perspective on the world changes. In their innocence, we are reminded of all that is good in the world. Perhaps, this is why we are always so shocked and saddened to hear about children fighting cancer? It seems so unjust (and it is).

According to the American Cancer Society (source: www.cancer.org), leukemia is the most common cancer in children and teens. Within the leukemia category, the most common are acute lymphocytic leukemia (ALL) and acute myeloid leukemia (AML). Although 5-year survival rates have increased, each year more than 2,000 children under age 19 die from cancer in the United States alone (source: www.childrenscancer.org).

In a recent talk at the Arizona Cord Blood Conference, Erik Praskins spoke openly about how his son’s life was saved thanks to a generous cord blood donation from a family he will probably never meet. His son, Dylan, was only 2 months old when he was diagnosed with leukemia, specifically ALL. His case was very serious. He was considered high-risk and required a stem cell transplant immediately. When a bone marrow donor could not be found, doctors turned to cord blood. Cord blood is more easily matched than bone marrow. It is also readily available if stored at birth. Recent studies have also suggested that a cord blood transplant for high-risk patients results in fewer cases of relapse (source: www.fredhutch.org).

Dylan was lucky in so many ways. His parents and doctors were quick to identify the cancer. They worked tirelessly to find an appropriate treatment for him. Little did they know on day one of this battle, that it would be the birth of another child somewhere in the world who would give Dylan a second chance. That child’s family literally gave life twice by donating their child’s cord blood instead of simply throwing it away. For this, Dylan’s family is eternally grateful. Just watch Erik’s face at the end of this video and you will see the gratitude spill over.

Perhaps their are angels among us?

Learn more about Dylan’s story here.

 

Save the Cord Foundation is proud to work with and support public cord blood donation programs around the world. We are especially proud of our work with the Arizona Public Cord Blood Program in our home state.
Find out how you can donate to this amazing public program
that helps patients, like Dylan, in Arizona and across the globe.

 

Cord Blood Experts Discuss Educational Approaches for Parents, Health Professionals & Students

Cord Blood Experts Discuss Educational Approaches for Parents, Health Professionals & Students

cord blood world europe 2017 educational approaches roundtableSave the Cord Foundation recently had the honor of attending Cord Blood World Europe 2017, part of the World Advanced Therapies & Regenerative Medicine Congress and World Precision Medicine Congress, held in London. This was a fantastic opportunity to hear excellent speakers such as Dr. Joanne Kurtzberg, Dr. Colleen Delaney, Dr. Paul Veys, Dr. Guy Sauvageau and many others speak about cord blood research and current uses for cord blood in the medical world. In addition, topics went beyond cord blood at times as experts discussed processing and uses for cord tissue as well as other perinatal stem cells. Regenerative medicine was a recurring theme throughout.

A great emphasis was placed on interacting with the expert presenters via lively roundtables and open panel discussions. Save the Cord Foundation was invited to host a roundtable discussion called “Educational Approaches.” We worked with attendees on new educational approaches addressing a variety of audiences, namely health professionals, expectant parents and our next generation of STEM professionals. Several of the participants in this roundtable discussion agreed to share their thoughts with the Save the Cord Foundation community. Below is a quick summary based on some of the most talked about presentations:

One of the most exciting presentations was made by Dr. Colleen Delaney of Nohla Therapeutics and Fred Hutchinson Cancer Research Center. Dr. Delaney presented “Ex-vivo Expanded Hematopoietic Stem/Progenitor Cell Therapies: The Road from a Patient Specific to Universal Donor Approach.” Participants in our roundtable commented that there were several key points made in this presentation that health professionals and parents needed to know about, for example:

After hearing Dr. Delaney’s presentation, I feel parents and health professionals need to realize why cord blood expansion techniques and the concept of the ‘universal donor’ which Dr. Delaney is exploring are so necessary. In particular, compared to patients of Caucasian descent, if a patient of mixed ethnicity is trying to find a match today the odds go down drastically. It is important for parents to know why this cord blood expansion technology led by Dr. Delaney is important and that happily it is perhaps just a few years away from being market ready. That potential is very encouraging.Mara Lucato (Create Cord Blood Bank Canada - www.createcordbank.com)

Another interesting presentation was made by Chiranya (Anjie) Prachaseri of Cryoviva in South East Asia, called “Perinatal Stem Cell Banking- Uses and Future Opportunities – A South East Asian Perspective.” This presentation emphasized the on-going problem with press and media coverage of cord blood which can often mislead parents and doctors. Prachaseri also discussed the fact that many parents do not know about the various accreditation groups who play a very important role in the industry.

Although the presentation focused mainly on South East Asia, Dr. Mareike Uhlmann from Stemlab, who participated in our roundtable, agreed it is crucial. . .

to ensure that the bank you want to use for storage is properly accredited and certified to guarantee that the parent’s hopes won’t be shattered in case a treatment is needed.Dr. Mareike Uhlmann (Stemlab - www.stemlab.ch)

Andre Gomes, also from Stemlab, stated how important it is to address the misinformation that is being given to our youth – the next generation of scientists, doctors, policy makers, etc. He applauded Prachaseri’s efforts of speaking to university students about cord blood and stem cell applications.

This has to be explained. More information must be given to young people otherwise we will always be fighting misinformation and confusing press. We need to move from the idea that ‘stem cells are bad’ to a discussion about the good and bad reasons for stem cell storage.Andre Gomes (Stemlab - www.stemlab.ch)

Finally, another presentation that prompted interesting discussion was made by Joana Correia of Exogenus Therapeutics. Correia presented “Umbilical Cord Blood Supply for the Development of Exo-Wound, an Exosome-based Product for Chronic Wounds.” Based on this presentation, roundtable participants saw opportunity for future STEM professionals who want to explore cellular expansion, delivery mechanisms, exosome extraction or even the shifts between translational and clinical applications. While these opportunities cannot be denied, several roundtable participants expressed caution reminding the group that cord blood stem cells are truly precious and should be used wisely.

Our collective responsibility, as scientists and educators, is to ensure that parents understand the true value of their newborn’s stem cells.Dr. Ayub Lulat (Create Cord Blood Bank Canada - www.createcordbank.com )
Challenges in cord blood education

Experts discuss challenges in cord blood education

We, at Save the Cord Foundation, could not agree more. Cord blood is rich in stem cells. If collected and stored properly, these stem cells could be currently used to treat more than 80 different life-threatening diseases including many blood cancers. Compared to bone marrow, it is much easier to match and carries less risk of Graft versus Host Disease. Impressive research is also underway around the globe to test cord blood’s potential in regenerative medicine. For example, there is ground-breaking research to potentially treat spinal cord injury, traumatic brain injury, hearing loss and diabetes all using cord blood.

This is why we tell every parent. . . do everything you can to save your baby’s cord blood. If you can donate it, then donate it. If you prefer to privately store it (for eventual use by your child or family member), then do it. Be proactive and plan ahead. Please don’t throw this valuable medical resource away. Save the cord.

Meet another cord blood expert: Dr. Curtis Cetrulo, Sr.

Learn about the current uses of cord blood and perinatal stem cells. . . click here.

 

 

London Puts the Spotlight on Cord Blood

London Puts the Spotlight on Cord Blood

cord blood spotlight london fact cba isct meetingsLondon is buzzing with talk about cord blood these days!  The 2017 ISCT Meetings kicked off last week with a 2-day focus on cord blood featuring experts from FACT, CBA, ISCT and ASBMT.  Our team was fortunate to be in attendance for this exclusive event.

The first day of the event focused on introducing banks to the FACT Cord Blood inspection process as well as the need for international standards. A portion of the day was also dedicated to explaining the role of the inspector and the requirements for becoming an inspector.

On the second day, meetings ran in tandem featuring a variety of topics and speakers. Attendees were encouraged to float between the two rooms and attend those meeting most important to them. In one room, FACT focused on real world applications of procedures and concepts. The day was designed to strengthen attendees quality assurance knowledge through a variety of presentations and exercises.

One of our favorite presentations and exercises looked at the implications and risks of having standards that are too strict given the potential new applications for cord blood in the near future. This topic was led by Ed Brindle, MSc, MLT from Insception Lifebank cord blood bank in Canada and an active volunteer on the FACT Accreditation Standards Committee.  He challenged attendees to work together to determine the pros and cons of changing certain acceptance criteria for cord blood units and the impact that these changes would have on current and future therapies.

Another notable presentation was made by Gesine Koegler, PhD who discussed the recent evolutions in the industry, namely the NetCord and WMDA partnership. Not only did Koegler give an overview of current trends in the industry but she spoke in great detail about the benefits of bringing WMDA and NetCord together under one umbrella. Born out of common goals, the new partnership signals another milestone for the industry as a whole.

CBA Agenda ISCT 2017

CBA Agenda ISCT 2017

Just upstairs, the Cord Blood Association together with ISCT and ABSMT held a full day of presentations. They hosted a truly dynamic group of speakers including Jaap Boelens, PhD. and Juliet Barker, MBBS. Dr. Joanne Kurtzberg and Dr. Elizabeth J. Shpall presented alongside key leaders in the field to cover topics such as cord expansion, cord blood versus haplo trends and breakthroughs in regenerative medicine. Each presentation was packed with useful information and the question/answer sessions were particularly beneficial.

Without a doubt the 2-day Cord Blood Spotlight was both highly educational and practical. As attendees, we learned about the importance of international standards for both public and private cord blood banks. We also enjoyed hearing how the latest research is advancing and then going back to the workshops to explore how the standards might change in the future based on these developments.

One thing is clear. . . the best public/private cord blood banks understand these details. They are actively making sure that the cord blood units they store are accessible and usable for current applications. They are also preparing today for what the near future holds, especially with regards to regenerative medicine.

 

Habla espanol ? Discover our selection of articles in Spanish.

medicina regerativa cordon umbilical

 

 

 

“Medicina regenerativa:
Salve vidas y reduzca costos de atención médica”

 

 

Share the Science: Dr. Tim Nelson from the MAYO Clinic, Strengthening the HLHS Heart with Cord Blood

Share the Science: Dr. Tim Nelson from the MAYO Clinic, Strengthening the HLHS Heart with Cord Blood

Cutting edge research at the MAYO Clinic is leading to new hope for individuals with HLHS Heart Syndrome and cord blood is a critical part of the story. Can cord blood strengthen the heart?  Dr. Timothy Nelson recently discussed his latest clinical trial on “Share the Science.”

Update: Dr. Nelson made his presentation live on “Share the Science” on May 17th, 2017. The recording is now available for viewing. Please click below.

Free Webinar: Save the Cord Foundation and Mediware, Inc. are proud to welcome Dr. Timothy Nelson for our next edition of Share the Science on May 17th, 2017. Share the Science is a free webinar series focused on the cord blood industry and the latest research in this field.  As always, we invite both health professionals and the general public to join us for this enlightening presentation.

Imagine the news. . . you are pregnant or perhaps just gave birth and your doctor tells you that your baby’s heart has not developed correctly. It is HLHS. Treatment typically involves a series of three intense surgeries as soon as the baby is born. If left untreated, HLHS is fatal soon after birth.

What is HLHS?

HLHS or Hypoplastic Left Heart Syndrome is a rare and complex congenital heart defect for which there is currently no cure.  Affecting more than 2,000 newborns in the United States each year, this disease is defined by underdevelopment.  According to the Mayo Clinic, “In HLHS, the left side of a child’s heart — the left ventricle, ascending aorta and left heart valves — is severely underdeveloped. The result is a heart with only a single functional ventricular chamber — the right ventricle — and a small ascending aorta.” (Source: Mayo Foundation for Medical Education and Research (MFMER))

At the MAYO Clinic, Dr. Timothy Nelson, M.D., Ph.D. leads an innovative team of physicians and scientists with one goal in mind. . . find a cure for HLHS.  As the director of Mayo Clinic’s Todd and Karen Wanek Family Program for Hypoplastic Left Heart Syndrome, and the the medical director of the Regenerative Medicine Consult Service, Dr. Nelson and his team are pursuing an innovative clinical trial using stem cells from cord blood to strengthen a baby’s heart following a HLHS diagnosis. The umbilical cord blood cells are processed in a specific manner in order to create highly concentrated stem cells that are injected into the heart at the time of the baby’s second open heart surgery.

The HLHS program has also recently created the HLHS consortium, a network of institutions that are participating in HLHS research. The consortium makes it easier for patients to participate in the overall research, including the umbilical cord blood collection, no matter their location.

Join us for this special presentation. . .

Dr. Timothy NELSON
from the Mayo Clinic’s
Todd and Karen Wanek Family Program for Hypoplastic Left Heart Syndrome

“Strengthening the HLHS Heart Using Umbilical Cord Blood”

Wednesday, May 17 | 2 p.m. – 3 p.m. Central Time

Free to register. Open to the public.

View the recording of SHARE THE SCIENCE with Dr. Timothy Nelson – Strengthening the HLHS Heart Using Umbilical Cord Blood

In this webinar, you will learn:

  • The importance of banking umbilical cord blood for babies with HLHS
  • What makes Mayo Clinic’s Todd and Karen Wanek Family Program for HLHS unique when it comes to umbilical cord blood banking
  • Details about the clinical trial using umbilical cord blood for babies with HLHS
  • How HLHS research at Mayo Clinic’s HLHS program is changing the future for HLHS individuals

 

Want to learn more?

Share the Science continues to be a popular series within the cord blood community and beyond. We welcome your input on the series and suggestions for future speakers. Give your feedback here.

powerhouses of science - cord blood research
Previous Share the Science presentations have been archived for your reference. Discover the work of leading scientists and cord blood industry experts through this educational series. View the archive now.

Share the Science is made possible thanks to the generous support of Mediware, Inc.

 

1237

About Save the Cord Foundation

Save the Cord Foundation, a 501c3 non-profit organization, was established to promote awareness of the life-saving benefits of cord blood based on unbiased and factual information. The Foundation educates parents, health professionals and the general public about the need to preserve this valuable medical resource while providing information on both public cord blood donation programs and family cord blood banks worldwide.

Support Save the Cord Foundation

Our mission depends on supporters like you. Please support our cause by making a donation or promoting our website and message where you can. We appreciate all the support!
(We NEVER ask for cash donations. Online donations are easier and safer. Thank you.)

© 2016 Save The Cord Foundation - All Rights Reserved · Powered By: Joker Media